We report a quantification of the decrease of effectiveness of antiviral agents directed to hepatitis C virus, when the agents are added during an ongoing infection in cell culture vs. when they are added at the beginning of the infection. Major determinants of the decrease of inhibitory activity are the time post-infection of inhibitor administration and viral replicative fitness. The efficacy decrease has been documented with antiviral assays involving the combination of the direct-acting antiviral agents, daclatasvir and sofosbuvir, and with the combination of the lethal mutagens, favipiravir and ribavirin. The results suggest that strict antiviral effectiveness assays in preclinical trials may involve the use of high fitness viral populations and the delayed administration of the agents, relative to infection onset.
Keywords: daclatasvir; delayed drug administration; direct acting antivirals; favipiravir; lethal mutagenesis; ribavirin; sofosbuvir; viral fitness.
Copyright © 2022 García-Crespo, Vázquez-Sirvent, Somovilla, Soria, Gallego, de Ávila, Martínez-González, Durán-Pastor, Domingo and Perales.